Truist Financial assumed coverage on shares of Coherus BioSciences (NASDAQ:CHRS – Get Rating) in a report published on Monday morning, The Fly reports. The firm issued a buy rating and a $24.00 target price on the biotechnology company’s stock. Several other research firms also recently weighed in on CHRS. HC Wainwright dropped their price target […]
Coherus BioSciences, Inc. (NASDAQ:CHRS – Get Rating) has earned a consensus recommendation of “Moderate Buy” from the eight research firms that are presently covering the stock, Marketbeat reports. Two equities research analysts have rated the stock with a hold recommendation and four have issued a buy recommendation on the company. The average 12-month price objective […]
Shares of Coherus BioSciences, Inc. (NASDAQ:CHRS – Get Rating) have earned a consensus rating of “Moderate Buy” from the eight research firms that are covering the stock, MarketBeat.com reports. Two investment analysts have rated the stock with a hold rating and four have assigned a buy rating to the company. The average 12-month target price […]
Coherus BioSciences, Inc. (NASDAQ:CHRS – Get Rating)’s stock price shot up 6.5% during trading on Monday . The stock traded as high as $8.41 and last traded at $8.39. 124,121 shares changed hands during mid-day trading, a decline of 89% from the average session volume of 1,107,739 shares. The stock had previously closed at $7.88. […]
Sargent Investment Group LLC trimmed its holdings in shares of Coherus BioSciences, Inc. (NASDAQ:CHRS – Get Rating) by 26.2% in the fourth quarter, according to its most recent filing with the SEC. The firm owned 11,200 shares of the biotechnology company’s stock after selling 3,970 shares during the period. Sargent Investment Group LLC’s holdings in […]